Senseo Quadrante Geant Casino

Posted on7/14/2022by admin

Sense took part in a week-long competition that brought together healthcare startups across health services, health IT, medical devices, biopharma, and diagnostics.

Sense Neuro won the competition in the area of Medical Devices and received accolades from the judges.

Congratulations to Geoffrey Klass, CEO of Sense Neuro Diagnostics on being selected as an Innovation Leader at the LSI 2021 Emerging Medtech Summit. For the second year in a row, Geoff Klass will be presenting to an exceptional group of investors and strategics.

With a massive selection of free slot games, our love of slots at Slotu means that we are constantly delivering new additions to the site each week. Our team works hard to hand pick, test and Promo Cafe Senseo Geant Casino list only the very best slot machines and online casinos intended for the Promo Cafe Senseo Geant Casino. Choose from our collection of beautiful blends, each one perfectly roasted and carefully ground. Each Original blend is perfectly roasted & carefully ground for an irresistible taste & smoothest crema.

Last year, Geoff took the floor to speak about our products and technology and how Sense is translating the research into clinical use and commercialization.

Watch the 2020 full presentation to learn more.

Cafetiere Senseo Quadrante Geant Casino

We are working to deliver a non-invasive brain scanner that can monitor the neurological status of a patient at any given time.

Sense would not have been possible without the help of our team of leaders, doctors, and trusted investors.

Watch Sense’s story through their experience.

Meeting the challenges of real-time brain monitoring

1 in 5 people who suffer strokes or severe traumatic brain injury each year die due to worsening conditions, delayed treatment, and lack of continuous brain monitoring.

Medical personnel has to rely on an amalgam of information – clinical exams, vital signs, implanted ICP monitors – to get an idea of whether the brain is bleeding in between CT/MRI scans.

Sense acts as an adjunct to CT/MRI and can detect active bleeding in the brain and alert medical personnel about worsening brain conditions.

The Sense device transmits a low power tailored electro-magnetic (EM) pulse in the RF range across the patient’s brain, and detects changes in the signal that may indicate acute bleeding, brain swelling, or blocked blood vessels.

Sense collects 720 data points every 40 seconds, 18 data points/second and facilitates on-going monitoring of neurological conditions.

Sense has the potential to revolutionize patient care and to change the game when it comes to real-time, continuous brain monitoring.

Sense Diagnostics is a clinical-stage medical technology company developing innovative products to address the need to detect, diagnose and monitor brain injuries and strokes. Our company seeks to become a global leader in neurological diagnostics through innovation and technology and by providing a product that may reduce health care costs and save millions of lives.

We aim to aid medical personnel and support them in their effort to detect and monitor brain conditions in real-time.

Geoff Klass

CEO

Serial Entrepreneur, Experienced Executive, Deep MedTech Network

Joe Korfhagen, PhD

Director, R&D

Neuroscience PhD, 8 years on technology

Dan Kincaid, JD

COO

Serial Entrepreneur, Managed Care Executive, Angel Investor

Ope Adeoye, MD

CMO

Emergency Medicine/Neurocritical Care, Clinical Trial Leader, Medical School Faculty

George Shaw, MD, PhD

CTO

Emergency Medicine, Physicist, Medical School Faculty

Matt Flaherty, MD

CCO

Neurology, Clinical Trial Leader, Medical School Faculty

Our team works diligently to make our innovative brain scanner a reality for patients. We are driven by our mission and are committed to impacting people's lives and enhancing neurological health globally.

SENSE Neuro Diagnostics Inc. has successfully completed its ‘first in human’ trial of the SENSE device in intracranial hemorrhage (ICH) patients in the neurological intensive care unit. The objective of this small pilot trial was safety and usability of the device in the clinical setting.

An additional objective was the detection of > 3 ml of ICH expansion (HE) using a non-invasive RF based technique. There were no significant adverse events (SAEs) from use of the device during continuous patient monitoring for up to 72 hours. Although the trial was small (n=10), the concordance of the SENSE readings with CT was 100% for the presence or absence of HE.

We look forward to the initiation of our pivotal clinical trial of the device in August of this year, as the COVID 19 pandemic permits.